Patent · US Active

Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV PreS1 and/or PreS2, and/or s-HBsAg regions of the HBV envelope protein

US11389532B2 · kind B2 · utility

1Cited by

2References

24Claims

0Family size

Assignees

University of Washington · US
ABACUS BIOSCIENCE, INC. · US

Inventors

Edward Clark · Seattle, US
Che-Leung Law · Bothell, US
Deborah Fuller · Middleton, US
Michael Gale · Seattle, US

Key dates

Filing date	Nov 15, 2018
Grant date	Jul 19, 2022
Priority date	—
Expiry date	Mar 9, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2730/10134
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.